Calyxt and Cibus announced that Calyxt has filed a registration statement on Form S-4 with the U.S. SEC on February 14. The combined company is expected to be renamed Cibus and remain listed on the Nasdaq Capital Market under the proposed ticker symbol CBUS. The Registration Statement contains a preliminary proxy statement / prospectus in connection with the previously announced merger of Calyxt and Cibus. Although the Registration Statement has not yet become effective and the information contained therein is subject to change, it provides important information about Calyxt and the proposed transactions.The entering into a definitive merger agreement was announced on January 17. The merger is expected to close in the second quarter of 2023, subject to customary closing conditions, including approval of the merger by the shareholders of Calyxt.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLXT:
- Calyxt, Inc. Announces its Filing of Registration Statement on Form S-4 in Connection with Merger with Cibus Global LLC
- Calyxt downgraded to Hold from Buy at Canaccord
- Calyxt More than Doubles on Cibus Deal
- Cellectis announces Calyxt, Cibus sign definitive merger agreement
- Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company